» Articles » PMID: 38462600

Membrane-associated RING-CH 7 Inhibits Stem-like Capacities of Bladder Cancer Cells by Interacting with Nucleotide-binding Oligomerization Domain Containing 1

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2024 Mar 11
PMID 38462600
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer stem-like capacities are major factors contributing to unfavorable prognosis. However, the associated molecular mechanisms underlying cancer stem-like cells (CSCs) maintain remain unclear. This study aimed to investigate the role of the ubiquitin E3 ligase membrane-associated RING-CH 7 (MARCH7) in bladder cancer cell CSCs.

Methods: Male BALB/c nude mice aged 4-5 weeks were utilized to generate bladder xenograft model. The expression levels of MARCHs were checked in online databases and our collected bladder tumors by quantitative real-time PCR (q-PCR) and immunohistochemistry (IHC). Next, we evaluated the stem-like capacities of bladder cancer cells with knockdown or overexpression of MARCH7 by assessing their spheroid-forming ability and spheroid size. Additionally, we conducted proliferation, colony formation, and transwell assays to validate the effects of MARCH7 on bladder cancer CSCs. The detailed molecular mechanism of MARCH7/NOD1 was validated by immunoprecipitation, dual luciferase, and in vitro ubiquitination assays. Co-immunoprecipitation experiments revealed that nucleotide-binding oligomerization domain-containing 1 (NOD1) is a substrate of MARCH7.

Results: We found that MARCH7 interacts with NOD1, leading to the ubiquitin-proteasome degradation of NOD1. Furthermore, our data suggest that NOD1 significantly enhances stem-like capacities such as proliferation and invasion abilities. The overexpressed MARCH7 counteracts the effects of NOD1 on bladder cancer CSCs in both in vivo and in vitro models.

Conclusion: Our findings indicate that MARCH7 functions as a tumor suppressor and inhibits the stem-like capacities of bladder tumor cells by promoting the ubiquitin-proteasome degradation of NOD1. Targeting the MARCH7/NOD1 pathway could be a promising therapeutic strategy for bladder cancer patients.

Citing Articles

Silencing CCT3 induces ferroptosis through the NOD1-NF-κB signaling pathway in bladder cancer.

Huang J, Luo Y, Wang Y, Wang S, Huang R, An Y Sci Rep. 2024; 14(1):26188.

PMID: 39478031 PMC: 11525567. DOI: 10.1038/s41598-024-76724-z.


The NEDD4/FLRT2 axis regulates NSCLC cell stemness.

Yang Y, Yan F, Gao Z, Li H, Wen S, Li Q Front Pharmacol. 2024; 15:1459978.

PMID: 39444619 PMC: 11496253. DOI: 10.3389/fphar.2024.1459978.

References
1.
Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z . Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):327-37. PMC: 3544173. DOI: 10.1158/1055-9965.EPI-09-0865. View

2.
Fang D, Kitamura H . Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches. Int J Urol. 2017; 25(1):7-17. DOI: 10.1111/iju.13404. View

3.
Wu X, Ye Y, Kiemeney L, Sulem P, Rafnar T, Matullo G . Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009; 41(9):991-5. PMC: 3313685. DOI: 10.1038/ng.421. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Hu Y, Zhang Y, Gao J, Lian X, Wang Y . The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data. Bioengineered. 2020; 11(1):572-581. PMC: 7250188. DOI: 10.1080/21655979.2020.1765500. View